Current investigational drugs in psoriasis. - Wikidata - awgldk - TriplyDB

Current investigational drugs in psoriasis.

Current investigational drugs in psoriasis.

http://www.wikidata.org/entity/Q37991748

about

Promising new treatments for psoriasis Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice.Psoriatic arthritis: an update.Design, synthesis and in vitro degradation of a novel co-drug for the treatment of psoriasis.Apremilast as a treatment for psoriasis.Th17 cell development: from the cradle to the grave.Advances in the genetics of spondyloarthritis and clinical implications.Apremilast for the treatment of psoriatic arthritis.Novel treatments with small molecules in psoriatic arthritis.Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports.Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis.

P2860

Q24598008-2A99192A-53BF-40F5-95AE-F96FA292E8F2 Q34099814-D926817A-D135-49BB-961D-D82D5C5F681C Q34144256-947A3CF6-9A55-42B8-BECB-5E6688B1A67A Q36417852-001A0A44-B657-48A8-BC28-C853DA2994A3 Q37327907-3048244E-A423-4029-93B1-4411B355A268 Q38019980-35C38197-9DD0-4C21-8F71-481B314AE2FB Q38081169-F970A59E-0614-4CB3-B8A0-5A45DA4373BD Q38114840-475E343D-8E5A-472A-9600-17FFC13E46DB Q38202205-F0739AC9-CA1D-4271-A008-82DBB885125E Q38229893-FEAAB157-F805-4639-8BE1-C2D462D9CD82 Q38632657-A823A364-ED69-4A92-9869-A6E2221610A4 Q40523577-0F7A262B-B756-49D1-BD07-885A0B52DEBD Q45176250-6760CCC0-D18A-4E57-A98A-9D9D9A15ECD3

P2860

Current investigational drugs in psoriasis.

http://www.wikidata.org/entity/Q37991748

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current investigational drugs in psoriasis.

@en

Current investigational drugs in psoriasis.

@nl

type

label

Current investigational drugs in psoriasis.

@en

Current investigational drugs in psoriasis.

@nl

prefLabel

Current investigational drugs in psoriasis.

@en

Current investigational drugs in psoriasis.

@nl

P1433

Q37991748-E60D0D44-6444-45AD-9F7A-7A248CAAF09E

P1476

Q37991748-10765530-3E0B-4FC6-A899-B8B48F3AF961

P2093

Q37991748-0E648E75-783A-4F81-8ED5-7437DDE870A5

Q37991748-2050A365-6EC5-472E-8864-91263F35EDF2

Q37991748-4F7FC3C5-0486-4344-9059-CB8E63F75283

P2860

Q37991748-055435AD-8CD9-4CC6-A7D7-489393385EE5

Q37991748-0D7A4FC5-ADBF-4C98-B9A6-BA8593F37D2E

Q37991748-103F58B7-F830-43C1-AB11-0803B3FF453B

Q37991748-1113C10D-7390-4658-BECC-53A23F3E1CFD

Q37991748-111AFDEE-700E-473F-8083-69E33DADE22E

Q37991748-127F0389-765A-4571-B7BC-B4E7C2A13EBD

Q37991748-16AE56B1-26DF-45F2-BEC0-312914750633

Q37991748-173174FC-19CE-4749-8DCE-AC5BEA00A4DD

Q37991748-1BC2B1FD-A28D-4D38-A78D-2CE75EAF328C

Q37991748-1CFDEADA-6DE3-4219-8E84-DAC76D93D35E

P304

Q37991748-F9096F87-BAF8-4EDA-84F2-2318513F77BB

P31

Q37991748-1D8D34B0-9FAA-4422-923D-1AB3CA2FBF38

P356

Q37991748-0A517597-6C30-42C0-9B1D-0BC2246BCB69

P407

Q37991748-D63A3729-9009-489E-BDE1-0C1E755E6FB4

P433

Q37991748-E8E25B64-34D4-4F08-9C24-D15301F46EA5

P478

Q37991748-EB49BBD5-5E99-4943-B3A1-5E13D9109112

P50

Q37991748-B10BB20F-8B6E-4B7D-BC67-DF0876BB6793

P577

Q37991748-535B1A3B-9DD0-43F8-99E7-C76E4BB2C38E

P698

Q37991748-C9B77C9C-CEF5-446C-8578-2D66BD2E251A

P356

13543784.2012.669372

P1433

Expert Opinion on Investigational Drugs

P1476

Current investigational drugs in psoriasis.

@en

P2093

Alan Menter

http://www.w3.org/2001/XMLSchema#string

Amanda Abramson

http://www.w3.org/2001/XMLSchema#string

Mahir Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase.

Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17

Certolizumab pegol for the treatment of Crohn's disease

Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1

IL-23 promotes tumour incidence and growth

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

P304

473-487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2012.669372

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22400979

http://www.w3.org/2001/XMLSchema#string